What can Big Pharma learn from an NYT bestseller?

What do blockbuster drugs have in common with Harry Potter and Lisbeth Salander? They're all mega-sellers in industries in which only two of every 7 big, risky bets pans out. So, Big Pharma could learn a trick or two from publishers, the Financial Times posits. Report

Suggested Articles

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.